6OP Stock Chart & Stats
€3.30
-€0.25(-3.50%)
At close: 4:00 PM EST
€3.30
-€0.25(-3.50%)
Day’s Range― - ―
52-Week Range€2.86 - €7.17
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€70.25M
Enterprise Value€102.63M
Total Cash (Recent Filing)€22.65M
Total Debt (Recent Filing)€35.38M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Sep 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding23,560,110
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.20
Price to Sales (P/S)43.87
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)€6.17M
Bulls Say, Bears Say
Bulls Say
Clinical PipelineA focused immunotherapy pipeline gives OSE exposure to large oncology and immuno-inflammation markets, while multiple clinical and preclinical programs can diversify development outcomes. Progress across several candidates may create successive partnering or licensing opportunities over the medium term.
Partnering ModelThe partnering model can provide upfront payments, research funding, milestones, and future royalties without requiring OSE to commercialize every program independently. Successful alliances could extend funding capacity and validate the platform while reducing the burden of late-stage commercialization.
Improved LeverageAlthough leverage remains elevated, improvement from the 2023 position indicates some balance-sheet repair over the longer period covered. A less leveraged structure than previously reported can modestly improve financial flexibility as management seeks to fund clinical development and partnerships.
Bears Say
Revenue VolatilityThe sharp revenue reversal demonstrates that reported income is highly dependent on irregular collaboration or milestone timing rather than a stable commercial base. Such volatility makes planning more difficult, weakens operating visibility, and increases dependence on future partnering events or financing.
Cash BurnA move from approximately €48.4M of positive operating and free cash flow in 2024 to substantial cash burn in 2025 materially raises funding dependency. Continued negative cash generation could constrain clinical investment and require additional financing before programs produce recurring returns.
Capital ErosionHeavy losses are eroding the capital base at the same time that debt is greater than equity, leaving less balance-sheet capacity to absorb further setbacks. If losses persist, OSE may face greater refinancing or equity-funding pressure, potentially diluting strategic flexibility.
OSE Immunotherapeutics SA News
6OP FAQ
What was OSE Immunotherapeutics SA’s price range in the past 12 months?
OSE Immunotherapeutics SA lowest stock price was €2.86 and its highest was €7.17 in the past 12 months.
What is OSE Immunotherapeutics SA’s market cap?
OSE Immunotherapeutics SA’s market cap is €70.25M.
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
OSE Immunotherapeutics SA’s upcoming earnings report date is Sep 28, 2026 which is in 21 days.
How were OSE Immunotherapeutics SA’s earnings last quarter?
OSE Immunotherapeutics SA released its earnings results on Apr 30, 2026. The company reported -€1.007 earnings per share for the quarter.
Is OSE Immunotherapeutics SA overvalued?
According to Wall Street analysts OSE Immunotherapeutics SA’s price is currently Overvalued.
Does OSE Immunotherapeutics SA pay dividends?
OSE Immunotherapeutics SA does not currently pay dividends.
What is OSE Immunotherapeutics SA’s EPS estimate?
OSE Immunotherapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OSE Immunotherapeutics SA have?
OSE Immunotherapeutics SA has 23,560,110 shares outstanding.
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
OSE Immunotherapeutics SA reported an EPS of -€1.007 in its last earnings report. Following the earnings report the stock price went down -9.202%.
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
Currently, no hedge funds are holding shares in DE:6OP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OSE Immunotherapeutics SA
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline features Tedopi, which is currently in Phase III clinical trials for non-small cell lung cancer, with further Phase II investigations ongoing for pancreatic and ovarian cancers. For infectious diseases, they are developing CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus. In oncology, their portfolio also includes BI 765063, in Phase I for solid tumors, and BiCKI, an innovative bispecific checkpoint inhibitor platform. BiCKI is engineered to counteract cancer's primary and secondary resistance mechanisms by targeting PD-1 alongside other novel pathways. Addressing autoimmune and inflammatory conditions, OSE Immunotherapeutics is progressing OSE-127, a humanized monoclonal antibody in Phase II trials for both ulcerative colitis and Sjögren's Syndrome. FR104 is undergoing Phase I development for rheumatoid arthritis, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company maintains strategic collaborations and partnerships with organizations such as GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. OSE Immunotherapeutics S.A. was formerly known as OSE Pharma SA until its name change in May 2016.